Are Wall Street Analysts Bullish on Regeneron Pharmaceuticals Stock?

Core Viewpoint - Regeneron Pharmaceuticals, Inc. has faced underperformance in its stock compared to broader market indices and biotechnology ETFs, despite a recent positive earnings report that exceeded expectations [2][3][4]. Company Overview - Regeneron Pharmaceuticals, based in Tarrytown, New York, is valued at $73.9 billion and has a portfolio of nine marketed drugs, including Eylea and Dupixent [1]. Stock Performance - Over the past year, Regeneron's stock has declined marginally, while the S&P 500 Index has increased by nearly 10.5% [2]. - Year-to-date, Regeneron stock is up 3.5%, compared to an 11.2% rise in the S&P 500 [2]. - The iShares Biotechnology ETF has outperformed Regeneron, gaining about 21.8% over the past year and 24.2% year-to-date [3]. Earnings Report - On October 28, Regeneron shares rose by 11.8% following the Q3 earnings report, which showed an adjusted EPS of $11.83, surpassing Wall Street's expectation of $9.44 [4]. - The company's revenue for the quarter was $3.8 billion, exceeding the forecast of $3.6 billion [4]. Analyst Expectations - For the current fiscal year ending in December, analysts project a 9.8% decline in EPS to $34.84 on a diluted basis [5]. - Regeneron has a mixed earnings surprise history, beating estimates in three of the last four quarters [5]. - Among 28 analysts covering Regeneron, the consensus rating is a "Moderate Buy," with 18 "Strong Buy" ratings, two "Moderate Buys," seven "Holds," and one "Moderate Sell" [5]. Price Targets - William Pickering from Bernstein recently assigned a "Buy" rating with a price target of $818, indicating an 11% potential upside [6]. - The mean price target is $755.22, representing a 2.5% premium to current levels, while the highest target of $910 suggests a 23.5% upside potential [6].